ALAMAB THERAPEUTICS INC.

PRINCETON, NJ · Founded 2017 · Biotech · Private

First-in-class monoclonal antibody therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · alamab.com

Sector
Biotech
Headquarters
PRINCETON, NJ
Founded
2017
Latest Form D
$11.8M, Aug 2017
Total capital
$11.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$11.8M
1 Form D · last Aug 2017
111 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
4
27 pending · first 2024
Rank in peer group#293 of 1449

Capital timeline

2017FEDERAL ↑EQUITY ↓Cumulative $11.8M1st Form D$11.8M
2017FEDERAL ↑EQUITY ↓Cumulative $11.8M1st Form D$11.8M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$11.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#293 · top 20%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • YANFENG ZHANGResearcherExecutive OfficerLinked by 4 patents
  • JEAN X. JIANGDirectorNamed in SEC Form D filings
  • JUMIN X. SUNDirectorNamed in SEC Form D filings
  • QINGXI WANGExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 31
  • PendingMethod Of Treating Neurological DisorderUSPTOApplication 19549989
  • PendingMethod Of Treating Bone CancersUSPTOApplication 19217871
  • PendingAnti-connexin Antibody FormulationsUSPTOApplication 19235455
Show all 31 patent records
  • Method Of Treating Neurological DisorderSep 3, 2026 · Application 19549989Pending
  • Method Of Treating Bone CancersApr 16, 2026 · Application 19217871Pending
  • Anti-connexin Antibody FormulationsFeb 19, 2026 · Application 19235455Pending
  • Connexin 43 Antibodies And Use ThereofSep 18, 2025 · Application 19019170Pending
  • Connexin 43 Antibodies And Use ThereofJul 17, 2025 · Application 18955222Pending
  • Anti-connexin Antibody FormulationsJul 15, 2025 · US 12,358,981Granted
  • Method Of Treating StrokeFeb 20, 2025 · Application 18803013Pending
  • Connexin 43 Antibodies And Use ThereofFeb 18, 2025 · US 12,227,561Granted
  • Connexin 43 Antibodies And Use ThereofJan 7, 2025 · US 12,187,794Granted
  • Method Of Treating OsteoarthritisJan 2, 2025 · Application 18757078Pending
  • Method Of Treating Bone CancersNov 28, 2024 · Application 18673081Pending
  • Anti-connexin Antibody FormulationsSep 19, 2024 · Application 18415511Pending
  • Anti-connexin Antibody FormulationsFeb 27, 2024 · US 11,912,764Granted
  • Anti-connexin Antibody FormulationsApplication 62909267Pending
  • Method Of Treating Neurological DisorderApplication PCTUS2026016669Pending
  • Method Of Treating Neurological DisorderApplication 63765394Pending
  • Connexin 43 Antibodies And Use ThereofApplication PCTUS2019025363Pending
  • Connexin 43 Antibodies And Use ThereofApplication 62800869Pending
  • Connexin 43 Antibodies And Use ThereofApplication 62651668Pending
  • Method Of Treating Bone CancersApplication PCTUS2025030838Pending
  • Method Of Treating StrokeApplication PCTUS2024042110Pending
  • Method Of Treating OsteoarthritisApplication PCTUS2024035862Pending
  • Method Of Treating Bone CancersApplication 63651826Pending
  • Method Of Treating Bone CancersApplication PCTUS2024030843Pending
  • Method Of Treating StrokeApplication 63519465Pending
  • Method Of Treating OsteoarthritisApplication 63511563Pending
  • Method Of Treating Bone CancersApplication 63504162Pending
  • Anti-connexin Antibody FormulationsApplication PCTUS2021044043Pending
  • Anto-connexin Antibody FormulationsApplication PCTUS2020054036Pending
  • Anti-connexin Antibody FormulationsApplication 63059502Pending
  • Connexin 43 Antibodies And Use ThereofApplication PCTUS2020016606Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .